Dysphagia is one of the most debilitating late effects of head and neck cancer (HNC) treatment, severely impacting quality of life and nutrition. Definitive assessment relies on videofluoroscopy (DIGEST), which requires specialized equipment and trained personnel, limiting its routine use in survivorship care. In contrast, patient-reported outcomes (PROs) offer a scalable, low-cost alternative, but translating them into clinical decisions remains challenging. This is where technology can make a difference. Q2BSTUDIO, as a software and technology development company, provides solutions to integrate PROs, predictive models, and automation into clinical practice.
Dysphagia risk stratification using PROs, such as MDADI questionnaires, captures the patient's perception of their swallowing. However, interpreting these responses to decide when to escalate care is not trivial. Traditional models rely on composite scores, but recent research shows that individual responses contain additional predictive information. Here, artificial intelligence (AI) and AI agents can analyze complex patterns in the data, identifying symptom combinations (e.g., cough, choking, weight loss) that correlate with higher risk. Q2BSTUDIO develops custom software that implements these models, enabling clinicians to receive real-time personalized alerts.
Technological infrastructure is key to deploying these solutions at scale. Using cloud (AWS/Azure) ensures patient data is stored securely and available from any device. Q2BSTUDIO offers cloud services to host PRO platforms, guaranteeing high availability and regulatory compliance, such as GDPR. Furthermore, cybersecurity is critical when handling health data. Implementing encryption, multi-factor authentication, and periodic audits is essential. Q2BSTUDIO integrates cybersecurity solutions that protect sensitive information from the design stage.
Another key pillar is business intelligence (BI/Power BI). PRO data combined with clinical variables (age, tumor type, radiation dose) can be visualized in interactive dashboards showing trends, alerts, and risk cohorts. This empowers survivorship teams to make evidence-based decisions. Q2BSTUDIO develops custom dashboards with Power BI, connecting multiple data sources (EHR, PROs, treatment records) to offer a unified patient view.
Process automation also plays an important role. For example, a workflow can be programmed so that when a PRO exceeds a risk threshold, it automatically triggers a notification to the specialist and generates a referral for videofluoroscopic evaluation. Q2BSTUDIO implements process automation that reduces administrative burden and accelerates care.
Finally, AI agents (virtual assistants) can interact with patients between visits, collecting PROs conversationally and answering frequent questions. These agents, trained on clinical and linguistic data, improve adherence and report accuracy. Q2BSTUDIO creates intelligent agents that integrate into web or mobile platforms, facilitating continuous data collection.
In conclusion, dysphagia risk stratification in head and neck cancer using PROs is a promising field that requires a multidisciplinary technological approach. Combining custom software, AI, cloud, cybersecurity, BI, and automation, healthcare organizations can implement more efficient, patient-centered surveillance programs. Q2BSTUDIO is positioned to support this process, offering technology solutions tailored to clinical and business needs.
